Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Craig R Jalbert
AddedMar 31, 2024
UpdatedMay 1, 2026
Craig R Jalbert

Craig R Jalbert

Board Member, Cambridge Heart

Craig R Jalbert's Career

Cambridge Heart
Cambridge Heart

Tewksbury, MA, US

Board Member· Board
Aptinyx
Aptinyx

Evanston, IL, US

Board Member· Board
Bellerophon Therapeutics be
Bellerophon Therapeutics be

Warren Township, NJ, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Craig R Jalbert's Career

Cambridge Heart
Cambridge Heart
Public$27.8M301990Tewksbury, MA, US
Board Member· Board

Leadership at Cambridge Heart

Dan LubinDan LubinCo-Founder
Jordan S. DavisJordan S. DavisCo-Founder
Jeffrey ArnoldJeffrey ArnoldCo-Founder
Aptinyx
Aptinyx
Public$273.9M122015Evanston, IL, US
Board Member· Board

Leadership at Aptinyx

Robert J. HombachRobert J. HombachBoard Member
Joseph MoskalJoseph MoskalFounder
Andy KiddAndy KiddCEO
Bellerophon Therapeutics be
Bellerophon Therapeutics be
Public$154M182009Warren Township, NJ, US
Board Member· Board

Leadership at Bellerophon Therapeutics be

Peter FernandesPeter FernandesCEO
Jonathan PeacockJonathan PeacockBoard Member
Naseem AminNaseem AminBoard Member
Dr Theodore T Wang \"Ted\"Dr Theodore T Wang \"Ted\"Board Member
Alyssa OpresnickAlyssa OpresnickBoard Member
Lisa KilliLisa KilliBoard Member

Similar to Bellerophon Therapeutics be

Lung BiotechnologyLung BiotechnologySilver Spring, MD, USPharmaceuticalsest. 1997Lung BiotechnologySilver Spring, MD, US · est. 1997

Lung Biotechnology PBC: Researching, developing, and marketing therapies for pulmonary arterial hypertension.

Public125
PulmatrixPulmatrixLexington, MA, USTherapeuticsest. 2003PulmatrixLexington, MA, US · est. 2003

Pulmatrix, Inc.: A US-based biotech firm specializing in therapies for chronic respiratory diseases.

Public · $148.4M24
Vero BiotechVero BiotechAtlanta, GA, USMedical Devicesest. 2006Vero BiotechAtlanta, GA, US · est. 2006

Vero Biotech: Innovating inhaled nitric oxide systems for unmet cardiopulmonary needs.

Public · $234.6M254
PulmokinePulmokineRensselaer, NY, USTherapiesest. 2007PulmokineRensselaer, NY, US · est. 2007

Pulmokine: A private biopharmaceutical firm based in Rensselaer, US.

Pre-Seed · $1M75

Craig R Jalbert's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Craig R Jalbert

Michael A. KramarzMichael A. KramarzBoard Member · Oncologix TechDonald GriffithDonald GriffithBoard Member · Sonnet BioTherapeutics HoldingsRob FrielRob FrielBoard Member · New York Life InsuranceAlan FuhrmanAlan FuhrmanBoard Member · SpringWorks TherapeuticsGary EllisGary EllisBoard Member · ToroJoel AckermanJoel AckermanBoard Member · Champions Oncology